Pfizer (PFE) Ticks Higher on Expanded Lyrica Indication
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $28.28 +1.65%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
Revenue Growth %: -4.9%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
Revenue Growth %: -4.9%
Join SI Premium – FREE
Pfizer (NYSE: PFE) shares are up early following news its Lyrica caps were approved by the FDA to manage neuropathic pain associated with spinal cord injury.
The stock is up 0.6 percent in early trade.
The stock is up 0.6 percent in early trade.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pfizer (PFE) PT Raised to $30 at JPMorgan
- Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
- Johnson & Johnson releases 2-year psoriasis drug data at dermatology meeting
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
